57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC.

@article{Gibbons201657OES,
  title={57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-na{\"i}ve patients (pts) with EGFR mutant NSCLC.},
  author={Don L. Gibbons and Laura Q M Chow and D J Kim and S-W Kim and Tammie C Yeh and Xinmiao Song and Haiyi Jiang and Robyn Taylor and Joyson J Karakunnel and Ben C. Creelan},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2016},
  volume={11 4 Suppl},
  pages={S79}
}

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

New advances in immunotherapy for non-small cell lung cancer.

American journal of translational research • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…